ReproCELL
4978.TTSE GROWTHChemicals
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥624m | ¥960m | ¥941m | ¥1.6bn | ¥1.3bn | ¥606m |
| Operating income | −¥609m | −¥401m | −¥387m | −¥337m | −¥471m | −¥768m |
| Ordinary income | −¥331m | −¥285m | −¥62m | −¥112m | −¥382m | −¥559m |
| Total assets | ¥9.2bn | ¥9.0bn | ¥8.8bn | ¥8.4bn | ¥8.2bn | ¥6.1bn |
| Net assets / equity | ¥8.7bn | ¥8.6bn | ¥8.4bn | ¥7.9bn | ¥7.5bn | ¥5.7bn |
| EPS (basic) | ¥-3.6 | ¥-3.29 | ¥-2.4 | ¥-3.52 | ¥-7.13 | ¥-13.96 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 69 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 189 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales |
|---|---|
| Medical Business | ¥281m |
| Research Support Business | ¥2.0bn |
| Adjustments & eliminations | — |
| Total | ¥2.2bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.